A novel adjuvant Ling Zhi-8 for cancer DNA vaccines

Human Vaccines

Volumn 7, Issue 11, 2011, Pages 1161-1164

  Chu, Ching Liang ^a   Chen, Dz Chi ^b   Lin, Chi Chen ^c,d  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Yeastern Biotech Co Ltd   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d Veteran General Hospital   (Taiwan)

Author keywords

Adjuvant; Cancer; Dendritic cell; DNA vaccine; Fungal immunomodulatory protein; LZ 8

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; HEAT SHOCK PROTEIN 70; IMMUNOLOGICAL ADJUVANT; LING ZHI 8 PROTEIN; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN PRESENTATION; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SURVIVAL; DENDRITE; DNA IMMUNIZATION; DRUG EFFECT; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG STORAGE; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; NEOPLASM; NONHUMAN; NOTE; VACCINE PRODUCTION;

EID: 81855227701     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.11.17753     Document Type: Note

References (33)

1. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992; 356:152-4; PMID:1545867; DOI:10.1038/356152a0.
2. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9; PMID:8456302; DOI:10.1126/science. 8456302.
3. Forde GM. Rapid-response vaccines - does DNA offer a solution? Nat Biotechnol 2005; 23:1059-62; PMID:16151391; DOI:10.1038/nbt0905-1059.
4. Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239:62-84; PMID:21198665; DOI:10.1111/j.1600-065X.2010.00980. x.
5. Hung CF, Ma B, Monie A, Tsen SW, Wu TC. Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther 2008; 8:421-39; PMID:18352847; DOI:10.1517/14712598.8.4.421.
6. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995; 13:2281-92; PMID:7545221.
7. Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A, Navarro-Teulon I. Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 2010; 59:1295-312; PMID:20532501; DOI:10.1007/s00262-010-0869-2.
8. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; DOI:10.1126/science.1129139.
9. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8:108-20; PMID:18219306; DOI:10.1038/nrc2326.
10. Signori E, Iurescia S, Massi E, Fioretti D, Chiarella P, De Robertis M, et al. DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother 2010; 59:1583-91; PMID:20390416; DOI:10.1007/s00262-010-0853-x.
11. Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7:175-91; PMID:18324888; DOI:10.1586/14760584.7.2.175.
12. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010; 2010:174378; PMID:20368780; DOI:10.1155/2010/174378.
13. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11:63-8; PMID:15812492; DOI:10.1038/nm1210.
14. Spreafico R, Ricciardi-Castagnoli P, Mortellaro A. The controversial relationship between NLRP3, alum, danger signals and the next-generation adjuvants. Eur J Immunol 2010; 40:638-42; PMID:20201020; DOI:10.1002/eji. 200940039.
15. Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines 2011; 10:539-50; PMID:21506650; DOI:10.1586/erv.11.21.
16. Dorgham K, Abadie V, Iga M, Hartley O, Gorochov G, Combadière B. Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination. Vaccine 2008; 26:3252-60; PMID:18479788; DOI:10.1016/j.vaccine. 2008.04.003.
17. Sanodiya BS, Thakur GS, Baghel RK, Prasad GB, Bisen PS. Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol 2009; 10:717-42; PMID:19939212; DOI:10.2174/138920109789978757.
18. Boh B, Berovic M, Zhang J, Zhi-Bin L. Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 2007; 13:265-301; PMID:17875480; DOI:10.1016/S1387-2656(07)13010-6.
19. Li QZ, Wang XF, Zhou XW. Recent status and prospects of the fungal immunomodulatory protein family. Crit Rev Biotechnol 2011; Epub on June 9.
20. Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, Ko K, et al. Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. J Biol Chem 1989; 264:472-8; PMID:2909532.
21. Murasugi A, Tanaka S, Komiyama N, Iwata N, Kino K, Tsunoo H, et al. Molecular cloning of a cDNA and a gene encoding an immunomodulatory protein, Ling Zhi-8, from a fungus, Ganoderma lucidum. J Biol Chem 1991; 266:2486-93; PMID:1990000.
22. van der Hem LG, van der Vliet JA, Bocken CF, Kino K, Hoitsma AJ, Tax WJ. Ling Zhi-8: studies of a new immunomodulating agent. Transplantation 1995; 60:438-43; PMID:7676490; DOI:10.1097/00007890-199509000-00006.
23. Miyasaka N, Inoue H, Totsuka T, Koike R, Kino K, Tsunoo H. An immunomodulatory protein, Ling Zhi-8, facilitates cellular interaction through modulation of adhesion molecules. Biochem Biophys Res Commun 1992; 186:385-90; PMID:1352970; DOI:10.1016/S0006-291X(05)80819-8.
24. Hsu HY, Hua KF, Wu WC, Hsu J, Weng ST, Lin TL, et al. Reishi immuno-modulation protein induces interleukin-2 expression via protein kinase-dependent signaling pathways within human T cells. J Cell Physiol 2008; 215:15-26; PMID:18189229; DOI:10.1002/jcp.21144.
25. Jeurink PV, Noguera CL, Savelkoul HF, Wichers HJ. Immunomodulatory capacity of fungal proteins on the cytokine production of human peripheral blood mononuclear cells. Int Immunopharmacol 2008; 8:1124-33; PMID:18550017; DOI:10.1016/j.intimp.2008.04.004.
26. Lin YL, Liang YC, Tseng YS, Huang HY, Chou SY, Hseu RS, et al. An immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NFkappaB and MAPK pathways. J Leukoc Biol 2009; 86:877-89; PMID:19498044; DOI:10.1189/jlb.0708441.
27. Lin CC, Yu YL, Shih CC, Liu KJ, Ou KL, Hong LZ, et al. A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. Cancer Immunol Immunother 2011; 60:1019-27; PMID:21499904; DOI:10.1007/s00262-011-1016-4.
28. Steinman RM. Dendritic cells: versatile controllers of the immune system. Nat Med 2007; 13:1155-9; PMID:17917664; DOI:10.1038/nm1643.
29. Buckwalter MR, Albert ML. Orchestration of the immune response by dendritic cells. Curr Biol 2009; 19:355-61; PMID:19439254; DOI:10.1016/j.cub. 2009.03.012.
30. Palucka K, Ueno H, Banchereau J. Recent developments in cancer vaccines. J Immunol 2011; 186:1325-31; PMID:21248270; DOI:10.4049/jimmunol.0902539.
31. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy 2010; 2:213-26; PMID:20635929; DOI:10.2217/imt.09.89.
32. Lai CY, Hung JT, Lin HH, Yu AL, Chen SH, Tsai YC, et al. Immunomodulatory and adjuvant activities of a polysaccharide extract of Ganoderma lucidum in vivo and in vitro. Vaccine 2010; 28:4945-54; PMID:20653103; DOI:10.1016/j. vaccine.2010.05.037.
33. Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15:361-7; PMID:19118066; DOI:10.1158/1078-0432.CCR-08-1725.